Abstract
Lactoferricin (LFcin) was initially identified as an antimicrobial peptide derived by pepsin digestion of lactoferrin (LF), a multifunctional innate-defense protein in milk. Various synthetic analogs of LFcin have also been reported. LFcin inhibits a diverse range of microorganisms such as gram-negative bacteria, gram-positive bacteria, yeast, filamentous fungi, and parasitic protozoa, including some antibiotic-resistant pathogens. LFcin kills target organisms by membrane perturbation and acts synergistically with some antimicrobial agents. LFcin exhibits numerous biological activities in common with those of LF. Whereas LFcin suppresses the activation of innate immunity by microbial components such as lipopolysaccharide (LPS) and CpG DNA, the peptide itself activates immunity. Administration of LFcin analogs has been shown to protect the host via direct antimicrobial activity and immunostimulatory effects in several infection models of mice. Here we present a comprehensive review of investigations of LFcin and related peptides.
Keywords: milk, lactoferrin, lactoferricin, lfcin, antimicrobial, peptide, immunomodulation, multifunctional
Current Pharmaceutical Design
Title: Lactoferricin Derived From Milk Protein Lactoferrin
Volume: 9 Issue: 16
Author(s): H. Wakabayashi, M. Takase and M. Tomita
Affiliation:
Keywords: milk, lactoferrin, lactoferricin, lfcin, antimicrobial, peptide, immunomodulation, multifunctional
Abstract: Lactoferricin (LFcin) was initially identified as an antimicrobial peptide derived by pepsin digestion of lactoferrin (LF), a multifunctional innate-defense protein in milk. Various synthetic analogs of LFcin have also been reported. LFcin inhibits a diverse range of microorganisms such as gram-negative bacteria, gram-positive bacteria, yeast, filamentous fungi, and parasitic protozoa, including some antibiotic-resistant pathogens. LFcin kills target organisms by membrane perturbation and acts synergistically with some antimicrobial agents. LFcin exhibits numerous biological activities in common with those of LF. Whereas LFcin suppresses the activation of innate immunity by microbial components such as lipopolysaccharide (LPS) and CpG DNA, the peptide itself activates immunity. Administration of LFcin analogs has been shown to protect the host via direct antimicrobial activity and immunostimulatory effects in several infection models of mice. Here we present a comprehensive review of investigations of LFcin and related peptides.
Export Options
About this article
Cite this article as:
Wakabayashi H., Takase M. and Tomita M., Lactoferricin Derived From Milk Protein Lactoferrin, Current Pharmaceutical Design 2003; 9 (16) . https://dx.doi.org/10.2174/1381612033454829
DOI https://dx.doi.org/10.2174/1381612033454829 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Designing Isoform-selective Inhibitors Against Classical HDACs for Effective Anticancer Therapy: Insight and Perspectives from In Silico
Current Drug Targets Evaluation of the in vitro Chemosensitivity and Correlation with Clinical Outcomes in Lung Cancer using the ATP-TCA
Anti-Cancer Agents in Medicinal Chemistry The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
Current Cancer Drug Targets Clinical Impact of Gene Expression Profiling on Oncology Diagnosis, Prognosis, and Treatment
Combinatorial Chemistry & High Throughput Screening Human Platelet Acetylcholinesterase Inhibition by Cyclophosphamide: A Combined Experimental and Computational Approach
CNS & Neurological Disorders - Drug Targets Gene and Stem Cell Therapy in the Treatment of Erectile Dysfunction and Pulmonary Hypertension; Potential Treatments for the Common Problem of Endothelial Dysfunction
Current Gene Therapy Ribozymes, DNAzymes and Small Interfering RNAs as Therapeutics
Current Drug Targets AIDS in African Nonhuman Primate Hosts of SIVs: A New Paradigm of SIV Infection
Current HIV Research Cardiac MRI in Infiltrative Disorders: A Concise Review
Current Cardiology Reviews The Role of Calcium Stores in Apoptosis and Autophagy
Current Molecular Medicine Randomized Controlled Clinical Trials in Mild-Moderate Ulcerative Colitis
Reviews on Recent Clinical Trials Nucleic Acid-based Technologies in Therapy of Malignant Gliomas
Current Pharmaceutical Biotechnology PROGRAMMED Cell Clearance: Molecular Mechanisms and Role in Autoimmune Disease, Chronic Inflammation, and Anti-Cancer Immune Responses
Current Immunology Reviews (Discontinued) Autophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy
Current Cancer Drug Targets Particle-based Vaccines for HIV-1 Infection
Current Drug Targets - Infectious Disorders The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Immunomodulatory Drugs (IMiDs) in Multiple Myeloma
Current Cancer Drug Targets Integrins in Bone Metastasis Formation and Potential Therapeutic Implications
Current Cancer Drug Targets The ALK Gene, An Attractive Target for Inhibitor Development
Current Topics in Medicinal Chemistry Relevance of Protein Isoforms in Proteomic Studies
Current Proteomics